Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

<p>Abstract</p> <p>Background</p> <p>To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study</p&...

Full description

Bibliographic Details
Main Authors: van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A
Format: Article
Language:English
Published: BMC 2012-09-01
Series:BMC Musculoskeletal Disorders
Subjects:
Rheumatoid arthritis
Infliximab
Therapeutic drug monitoring
Serum trough levels
Anti-infliximab antibodies
Low disease activity
Online Access:http://www.biomedcentral.com/1471-2474/13/184

Internet

http://www.biomedcentral.com/1471-2474/13/184

Similar Items